ClinicalTrials.gg
CompletedNCT02171468Updated Jun 24, 2014

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

A Phase 1 interventional study of Dabigatran high dose and Dabigatran low dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days) in healthy male subjects between Japanese and Caucasians

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese or Caucasian healthy male subjects according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead , clinical laboratory tests

    • No finding of clinical relevance
    • No evidence of a concomitant disease
    • Caucasian subjects are from a well-defined Caucasian population, both parents of Caucasians, the subjects can understand the subject information for in English and the subjects have lived 8 or less than 8 years in Japan
  2. Age: ≥20 and ≤45 years
  3. (BMI): ≥18.5 and ≤29.9 kg/m2
  4. Signed and dated written informed consent before admission to the trial site

Exclusion criteria

Exclusion Criteria:

  1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Subject can not use an adequate form of from the time of the first dose on Day 1 up to end-of study examination
  3. Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
  4. History of orthostatic hypotension, clinically significant current or past fainting spells or blackouts
  5. Chronic or relevant acute infections
  6. History of

    • allergy/ (including drug allergy) which is deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever)
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic diseases
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
  8. Use of aspirin (including over-the-counter medications), antipletelet agents like ticlopidine or dipyridamole, chronic administration of nonsteroidal antiinflammatory drugs , coumadin like anticoagulants, chronic use of , heparin or fibrinolytic agents within 28 days prior to administration up to end-of-study examination
  9. Participation in another trial with an drug within 3 months prior to administration up to end-of-study examination
  10. Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial)
  11. Alcohol abuse (more than 60 g/day; confirmed by interview)
  12. Drug abuse (confirmed by interview)
  13. Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination)
  14. Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination)
  15. Any laboratory value outside the reference range that is of clinical relevance
  16. Known hypersensitivity to the investigational drug or its
  17. Subject who was judged ineligible by the investigator or the sub-investigator
  18. History of any familial bleeding disorder
  19. \<15 x 10**4 /microL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Dabigatran high dose

    Drug: Dabigatran high dose

  • Experimental
    Dabigatran low dose

    Drug: Dabigatran low dose

Interventions

  • DrugDabigatran high dose
  • DrugDabigatran low dose
06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events

    Time frame: up to 10 days

  2. Changes in QT(c) intervals

    Time frame: up to 7 days

  3. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)

    Time frame: up to 7 days

  4. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 7 days

Secondary outcomes

  1. Cmax (maximum measured concentration)

    Time frame: day 1

  2. tmax (time from dosing to maximum measured concentration)

    Time frame: day 1

  3. AUCτ,1 (area under the concentration-time curve over a uniform dosing interval τ after administration of single dose on Day 1)

    Time frame: day 1

  4. tmax,ss (time from last dosing to maximum concentration at steady state)

    Time frame: up to 7 days

  5. Cmin,ss (minimum concentration at steady state over a uniform dosing interval τ)

    Time frame: up to 7 days

  6. λz,ss (terminal rate constant at steady state)

    Time frame: up to 7 days

  7. t1/2,ss (terminal half-life at steady state)

    Time frame: up to 7 days

  8. MRTpo,ss (mean residence time in the body at steady state after oral administration)

    Time frame: up to 7 days

  9. CL/F,ss (apparent clearance in the plasma at steady state after extravascular multiple dose administration)

    Time frame: up to 7 days

  10. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)

    Time frame: up to 7 days

  11. RA,Cmax,13 (accumulation ratio calculated as Cmax,ss/Cmax)

    Time frame: up to 7 days

  12. RA,AUC,13 (accumulation ratio calculated as AUCτ,ss/AUCτ,1)

    Time frame: up to 7 days

  13. area under the curve for activated partial thromboplastin time (aPTT)

    Time frame: 0 - 12 hours after adminstration on day 1 and day 7

  14. area under the curve for ecarin clotting time (ECT)

    Time frame: 0 - 12 hours after adminstration on day 1 and day 7

  15. comparison of trough concentrations

    Time frame: after doses 3, 5, 7, 9, 11 and 13

  16. comparison of trough concentrations morning versus evening

    Time frame: after doses 9, 10, 11, 12, 13

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
May 2006
Primary completionActual
Jul 2006
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171468
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
May 2006
Primary completion
Jul 2006
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion